Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer
暂无分享,去创建一个
E. Petricoin | P. Singh | C. Der | M. Pierobon | A. Cox | Guo-Fang Zhang | E. Knudsen | T. Hayes | A. Witkiewicz | N. Tran | C. Lyssiotis | J. Macdonald | A. Tikunov | H. Ying | S. Peng | V. Gunda | Alec C. Kimmelman | Andrew M. Waters | Kirsten L. Bryant | Bjoern Papke | Nina V. Chaika | J. Diehl | Samuel D. George | G. A. Hobbs | Liang Yan | Clint A. Stalnecker | Daniel Zeitouni | Jennifer E. Klomp | Garima Tomar | G. Goode | Yingxue Wang
[1] Mark R. Marten,et al. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1 , 2021, Autophagy.
[2] J. Yap,et al. Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers , 2019, Nature Medicine.
[3] Laura E. Herring,et al. KRAS Suppression-Induced Degradation of MYC Is Antagonized by a MEK5-ERK5 Compensatory Mechanism. , 2018, Cancer cell.
[4] Channing J Der,et al. KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer. , 2018, Cold Spring Harbor perspectives in medicine.
[5] Robert E Denroche,et al. Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer. , 2018, Cancer discovery.
[6] W. R. Bishop,et al. Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors. , 2018, JCI insight.
[7] P. Zarrinkar,et al. Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor , 2018, Cell.
[8] Manish R. Patel,et al. First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study. , 2017, Cancer discovery.
[9] Quan P. Ly,et al. MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer. , 2017, Cancer cell.
[10] Richard A. Moore,et al. Pyruvate Kinase Inhibits Proliferation during Postnatal Cerebellar Neurogenesis and Suppresses Medulloblastoma Formation. , 2017, Cancer research.
[11] E. Petricoin,et al. Enrichment of PI3K-AKT–mTOR Pathway Activation in Hepatic Metastases from Breast Cancer , 2017, Clinical Cancer Research.
[12] C. Der,et al. Drugging RAS: Know the enemy , 2017, Science.
[13] E. White,et al. Autophagy, Metabolism, and Cancer , 2017, Cold Spring Harbor symposia on quantitative biology.
[14] G. Hospers,et al. Society of Surgical Oncology 70th Annual Cancer Symposium , 2017, Annals of Surgical Oncology.
[15] Rebecca Rojansky,et al. Elimination of paternal mitochondria in mouse embryos occurs through autophagic degradation dependent on PARKIN and MUL1 , 2016, eLife.
[16] M. Wasik,et al. 13C MRS and LC–MS Flux Analysis of Tumor Intermediary Metabolism , 2016, Front. Oncol..
[17] P. Stephens,et al. Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2. , 2016, Cancer cell.
[18] E. Sokol,et al. AMPK promotes tolerance to Ras pathway inhibition by activating autophagy , 2016, Oncogene.
[19] Shih-Hsun Chen,et al. Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120. , 2016, Cancer discovery.
[20] L. Scorrano,et al. Mitochondrial Cristae: Where Beauty Meets Functionality. , 2016, Trends in biochemical sciences.
[21] E. Petricoin,et al. Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression. , 2016, Cancer cell.
[22] E. Petricoin,et al. Functional signaling pathway analysis of lung adenocarcinomas identifies novel therapeutic targets for KRAS mutant tumors , 2015, Oncotarget.
[23] John M Asara,et al. Small Molecule Inhibition of the Autophagy Kinase ULK1 and Identification of ULK1 Substrates. , 2015, Molecular cell.
[24] L. Liotta,et al. Safety and Biologic Response of Pre-operative Autophagy Inhibition in Combination with Gemcitabine in Patients with Pancreatic Adenocarcinoma , 2015, Annals of Surgical Oncology.
[25] A. Kimmelman,et al. Metabolic Dependencies in RAS-Driven Cancers , 2015, Clinical Cancer Research.
[26] I. Ganley,et al. Pharmacological Inhibition of ULK1 Kinase Blocks Mammalian Target of Rapamycin (mTOR)-dependent Autophagy* , 2015, The Journal of Biological Chemistry.
[27] David F. Kashatus,et al. Erk2 phosphorylation of Drp1 promotes mitochondrial fission and MAPK-driven tumor growth. , 2015, Molecular cell.
[28] J. Chipuk,et al. Mitochondrial division is requisite to RAS-induced transformation and targeted by oncogenic MAPK pathway inhibitors. , 2015, Molecular cell.
[29] S. Fesik,et al. Drugging the undruggable RAS: Mission Possible? , 2014, Nature Reviews Drug Discovery.
[30] John M. Asara,et al. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function , 2014, Nature.
[31] J. Meyerhardt,et al. Phase II and pharmacodynamic study of autophagy inhibition using hydroxychloroquine in patients with metastatic pancreatic adenocarcinoma. , 2014, The oncologist.
[32] Gerald C. Chu,et al. Autophagy is critical for pancreatic tumor growth and progression in tumors with p53 alterations. , 2014, Cancer discovery.
[33] D. Esposito,et al. Dragging ras back in the ring. , 2014, Cancer cell.
[34] M. Herlyn,et al. Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma. , 2014, The Journal of clinical investigation.
[35] Channing J Der,et al. KRAS: feeding pancreatic cancer proliferation. , 2014, Trends in biochemical sciences.
[36] D. Bar-Sagi,et al. Determining the macropinocytic index of cells through a quantitative image-based assay , 2014, Nature Protocols.
[37] Eileen White,et al. Exploiting the bad eating habits of Ras-driven cancers , 2013, Genes & development.
[38] Christian M. Metallo,et al. Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells , 2013, Nature.
[39] Tomasz Arodz,et al. Systems Analysis of the NCI-60 Cancer Cell Lines by Alignment of Protein Pathway Activation Modules with “-OMIC” Data Fields and Therapeutic Response Signatures , 2013, Molecular Cancer Research.
[40] Shuxia Zhao,et al. Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. , 2013, Cancer discovery.
[41] Justin Guinney,et al. GSVA: gene set variation analysis for microarray and RNA-Seq data , 2013, BMC Bioinformatics.
[42] M. Fukuda,et al. Faculty Opinions recommendation of Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. , 2012 .
[43] Jean-Charles Portais,et al. IsoCor: correcting MS data in isotope labeling experiments , 2012, Bioinform..
[44] Bond-Smith Giles,et al. Only women with symptoms need to have their breast implants removed, says government , 2012 .
[45] C. Galbán,et al. Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice. , 2012, The Journal of clinical investigation.
[46] H. Ke,et al. Beclin1 Controls the Levels of p53 by Regulating the Deubiquitination Activity of USP10 and USP13 , 2011, Cell.
[47] R. Hruban,et al. Tumor Engraftment in Nude Mice and Enrichment in Stroma- Related Gene Pathways Predict Poor Survival and Resistance to Gemcitabine in Patients with Pancreatic Cancer , 2011, Clinical Cancer Research.
[48] Marc Liesa,et al. Pancreatic cancers require autophagy for tumor growth. , 2011, Genes & development.
[49] H. Coller,et al. Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis. , 2011, Genes & development.
[50] Guo-Fang Zhang,et al. Isotopomer enrichment assay for very short chain fatty acids and its metabolic applications. , 2011, Analytical biochemistry.
[51] B. Viollet,et al. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1 , 2011, Nature Cell Biology.
[52] Eileen White,et al. Autophagy and Metabolism , 2010, Science.
[53] J. Debnath,et al. PLIC proteins or ubiquilins regulate autophagy‐dependent cell survival during nutrient starvation , 2009, EMBO reports.
[54] A. Yamamoto,et al. LC3, GABARAP and GATE16 localize to autophagosomal membrane depending on form-II formation , 2004, Journal of Cell Science.
[55] E. Petricoin,et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. , 2003, Cancer cell.
[56] H. Brunengraber,et al. Correction of 13C mass isotopomer distributions for natural stable isotope abundance. , 1996, Journal of mass spectrometry : JMS.
[57] P. Singh,et al. Hypoxia-Induced Metabolomic Alterations in Pancreatic Cancer Cells. , 2018, Methods in molecular biology.
[58] E. Petricoin,et al. Reverse Phase Protein Microarrays. , 2017, Methods in molecular biology.
[59] A. Giuliano,et al. Guidelines for Guidelines: An Assessment of the American Society of Breast Surgeons Contralateral Prophylactic Mastectomy Consensus Statement , 2016, Annals of Surgical Oncology.
[60] Lee,et al. Editorial :Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). DOI: 10.1080/15548627.2015.1100356;WOS:000373595400001; 2-s2.0-85013763791&;PMID: 26799652 , 2016 .
[61] N. Bardeesy,et al. Pancreatic adenocarcinoma. , 2014, The New England journal of medicine.
[62] M. Signore,et al. Antibody validation by Western blotting. , 2012, Methods in molecular biology.
[63] T. P. Neufeld,et al. Guidelines for the use and interpretation of assays for monitoring autophage , 2012 .
[64] P. M. Campbell,et al. K-Ras promotes growth transformation and invasion of immortalized human pancreatic cells by Raf and phosphatidylinositol 3-kinase signaling. , 2007, Cancer research.